Tag Archives: Jazz Pharmaceuticals

August, 2018

July, 2018

August, 2017

July, 2017

June, 2017

August, 2016

  • 1 August

    Jazz Enters Hematological Malignancies Licensing Deal with Pfenex

    DUBLIN and SAN DIEGO, July 28, 2016 /PRNewswire/ — Jazz Pharmaceuticals plc(Nasdaq: JAZZ) and Pfenex Inc. (NYSE MKT: PFNX) today announced an agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematology product candidates.  The agreement also includes an option for Jazz Pharmaceuticals …

May, 2016

  • 12 May

    Jazz Pharmaceuticals Purchases Alize Pharma

    Alizé Pharma II announces today that a subsidiary of Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has acquired 100% of its shares. This all-cash transaction closed in March 2016. The deal is valued at up to €18 million, including an upfront payment of €8 million and potential payments of up to €10 …

March, 2016

  • 31 March

    FDA Approves Jazz Pharmaceuticals’ Rare Liver Disease Drug

    DUBLIN, March 30, 2016 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the United States (U.S.) Food and Drug Administration (FDA) granted marketing approval for Defitelio® (defibrotide sodium) for the treatment of adult and pediatric patients with hepatic VOD, also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary …